{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T16:03:49Z","timestamp":1704902629766},"reference-count":66,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,8,3]],"date-time":"2006-08-03T00:00:00Z","timestamp":1154563200000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Secondary hyperparathyroidism (SHPT) leads not only to bone disorders, but also to cardiovascular complications in long\u2010term dialysis patients. Conventional treatment with calcium (Ca) supplement, phosphate (P) binders and active vitamin D analogs lead in part to amelioration of SHPT, but are simultaneously associated with unacceptable side\u2010effects, including hypercalcemia, hyperphosphatemia, and increased Ca\u2003\u00d7\u2003P products, which are the risk factors for cardiovascular disease in dialysis patients. Conventional treatment has been unable to facilitate the attainment of optimal management of SHPT proposed in the K\/DOQI guidelines. Cinacalcet HCl (cinacalcet), a novel calcimimetic compound, restores the sensitivity of the Ca\u2010sensing receptor in parathyroid cells, and decreases serum parathyroid hormone (PTH) without introducing hypercalcemia or hyperphosphatemia. Cinacalcet treatment enables a significant number of patients to achieve the K\/DOQI guideline. Based on experimental data, calcimimetics could ameliorate cardiovascular calcification and remodeling in uremic rats with SHPT. Clinical trials have shown that cinacalcet significantly reduced the risks of parathyroidectomy, fracture and cardiovascular hospitalization among long\u2010term dialysis patients with SHPT. Parathyroid intervention therapy (parathyroidectomy and percutaneous direct injection) is also a useful alternative. In the present article, we review novel therapeutic strategies for SHPT.<\/jats:p>","DOI":"10.1111\/j.1744-9987.2006.00389.x","type":"journal-article","created":{"date-parts":[[2006,8,3]],"date-time":"2006-08-03T09:36:12Z","timestamp":1154597772000},"page":"355-363","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic Strategies for Secondary Hyperparathyroidism in Dialysis Patients"],"prefix":"10.1111","volume":"10","author":[{"given":"Hiroaki","family":"Ogata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Koiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Kinugasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,8,3]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2003.50095"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.292"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422003"},{"key":"e_1_2_7_5_2","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO4, Ca \u00d7 P4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh SK","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00185.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.99.18.2434"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.060002472.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2005.00310.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1774-9987.2005.00208.x"},{"issue":"3","key":"e_1_2_7_11_2","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation.","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00720.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000050224.03126.AD"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(12)80446-X"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00331.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-61-4-601"},{"key":"e_1_2_7_17_2","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1681\/ASN.V9101845","article-title":"High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro","volume":"9","author":"Almaden Y","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00042.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(99)00169-6"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh827"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005010052"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116720"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2005.00302.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.469"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1997.41"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.suppl_1.66"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00302.2004"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90617-Y"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.87.3.1309"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2005.00301.x"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(00)70064-3"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2005.00279.x"},{"key":"e_1_2_7_33_2","first-page":"755A","article-title":"Effects of PB\u201094 (sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis patients\u2010 A randomized, open label, dose\u2010titration study of PB\u201094 versus Caltan","volume":"12","author":"Kinugasa E","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00126.x"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00600.x"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00434.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1774-9987.2005.00215.x"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00171.x"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.27425"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.1998.v32.pm9708607"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1774-9987.2004.00191.x"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1993.280"},{"key":"e_1_2_7_43_2","first-page":"200A","article-title":"A comparison of 22\u2010oxa1,25\u2010dihydroxyvitamin D3 and 1,25\u2010dihydroxyvitamin D3 in the treatment in hemodialysis patients\u2010 a crossover study","volume":"14","author":"Ogata H","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh329"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(00)70198-3"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh1002"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00575.x"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70260-X"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg513"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004070573"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022536"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.06.019"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031633"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.67139.x"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00596.x"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.67103.x"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000141016.20133.33"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh829"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh966"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2005.04.013"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.66015.x"},{"key":"e_1_2_7_62_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000161997.24797.c0"},{"key":"e_1_2_7_63_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000056188.23717.E5"},{"key":"e_1_2_7_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.9.1553"},{"key":"e_1_2_7_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1774-9987.2005.00214.x"},{"key":"e_1_2_7_66_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004030236"},{"key":"e_1_2_7_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1774-9987.2005.00213.x"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1744-9987.2006.00389.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1744-9987.2006.00389.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T14:06:39Z","timestamp":1697292399000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1744-9987.2006.00389.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1111\/j.1744-9987.2006.00389.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1744-9987.2006.00389.x","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}